Close
Achema middle east
swop processing & packaging

Just Announced: AI in Drug Discovery 2026 Agenda

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Ensera Launches as New Brand Identity for SteriPack

New trading name reflects expanded expertise across design, manufacturing,...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

SAE Media Group unveils the full agenda for AI in Drug Discovery Conference 400 ticket saving ends 7 November 2025.

2026, highlighting the technologies and strategies driving

transformation in pharma R&D. £400 ticket saving ends 7 November

FOR IMMEDIATE RELEASE 2025

SAE Media Group has officially unveiled the agenda for AI in Drug Discovery 2026, taking place 9–10 March 2026 in London. The programme highlights how artificial intelligence is being deployed across pharmaceutical R&D to accelerate discovery, reduce costs, and improve outcomes.

With the global AI in drug discovery market projected to reach $8.53 billion by 2030, this year’s event reflects a shift from pilot projects to enterprise-wide implementation. The agenda features cutting-edge case studies, platform demonstrations, and strategic insights from leading pharma, biotech, and AI technology providers.

Agenda Highlights:

  • Foundation models for target identification and disease understanding
  • LLMs in computational chemistry and molecular design
  • Advanced cell models and simulations enabling animal reduction
  • Scaling AI systems across global R&D portfolios
  • Tackling integration barriers: data quality, interoperability, regulatory alignment, and ethical AI
  • Market outlook and investment trends as AI adoption accelerates

The speaker line-up includes senior leaders from leading organisations such as GSK,

Novartis, Eli Lilly, Novo Nordisk, Recursion, and Insilico Medicine. Attendees will hear

directly from those driving AI integration across molecule design, clinical trial optimisation, and preclinical modelling.

“This year’s agenda is designed to help pharma and biotech teams move from concept to implementation,” said Katie Ogden, Portfolio Manager at SAE Media Group. “We’re bringing together the people and platforms that are actively shaping the future of drug discovery.”

Register Now – £400 ticket saving Ends 7 November

Delegates who book before 7 November 2025 will save £400 on their pass. View the brochure – https://www.smgconferences.com/pharmaceuticals/uk/conference/drug-discovery

Latest stories

Related stories

Ensera Launches as New Brand Identity for SteriPack

New trading name reflects expanded expertise across design, manufacturing,...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »